Helius Medical Technologies Expands Stroke Clinical Program With Participation Of Shepherd Center
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Technologies, Inc. (NASDAQ:HSDT) has expanded its clinical program for the Portable Neuromodulation Stimulator (PoNS) device to include stroke recovery, partnering with Shepherd Center. This collaboration marks Shepherd Center as the third site in Helius' U.S. registrational program for PoNS in stroke rehabilitation, focusing on gait and balance deficits in chronic stroke survivors. The study aims to support a regulatory submission for marketing authorization in the U.S. by 2025. Shepherd Center's involvement builds on its previous participation in the PoNS Therapeutic Experience Program for multiple sclerosis, highlighting the potential of PoNS Therapy in improving gait rehabilitation.
April 24, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Helius Medical Technologies expands its stroke clinical program with Shepherd Center for its PoNS device, aiming for U.S. marketing authorization by 2025.
The expansion of Helius Medical's clinical program for the PoNS device into stroke recovery, in partnership with a top neurorehabilitation hospital, is a significant step towards broadening the device's market and therapeutic applications. This move not only demonstrates the company's commitment to advancing neurorehabilitation but also potentially opens up a new market segment in stroke recovery. The anticipation of regulatory submission by 2025 for marketing authorization in the U.S. indicates a positive trajectory for the company's growth and could lead to increased investor interest and stock value in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100